Alpha Cognition Inc
ACOG
Ранг среди акций
#20011
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Цена акции
$8.63
Последняя синхронизация: 2026-10-21
Рыночная капитализация
$134.04M
Изменение (1 день)
0.23%
Изменение (1 год)
71.57%
Страна
US
Торговля Alpha Cognition Inc (ACOG)
Категория
Healthcare
История цены акций Alpha Cognition Inc (ACOG)
Наивысшая цена закрытия: $5.46 2024-12-01
Наименьшая цена закрытия: $18.75 2021-06-01
Наименьшая цена закрытия: $18.75 2021-06-01
История цены акций Alpha Cognition Inc с 2021 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $756.75 | 7.56% |
CH
|
